Recruiting

Observational Study

Sponsor:

Arbor Research Collaborative for Health

Code:

NCT04970056

Conditions

Pancreas Cancer

Pancreas Cyst

Pancreatic Ductal Adenocarcinoma

Genetic Predisposition

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Conditions

Pancreas Cancer

Pancreas Cyst

Pancreatic Ductal Adenocarcinoma

Genetic Predisposition

Study ID

NCT04970056

Start date

Sep 18, 2020

Status verified date

Jul, 2026

Completion date

Dec 31, 2030

Anticipated

Primary completion date

Dec 31, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

Individuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database:

Cohort 1

Individuals without history of PDAC meeting any of the following criteria:

1. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family
3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family
4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+
5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+
6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+

Cohort 2

Individuals without history of PDAC meeting any of the following criteria:

1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+
2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family
3. 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member

Cohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)

Cohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.

Cohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.

Cohort 6a

Individuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria:

1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11

Cohort 6b

Individuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria:

1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
3. Diagnosed ≤ age 45

Cohort 6c Individuals with newly diagnosed early stage (stage I or stage II) PDAC seen at a PRECEDE site that do not meet the criteria for 6a or 6b.

Cohort 6d Individuals with PDAC seen at a PRECEDE site that do not meet the criteria for 6a, 6b, or 6c.

Cyst Cohort Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)

Exclusion Criteria:

  • Individuals not meeting the criteria above.

Study Design

Enrollment

20000 participants

Anticipated

Interventions and Outcome Measures

Arms

Cohort 1

Individuals without history of PDAC meeting any of the following criteria:

1. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family
3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family
4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+
5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+
6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+

Cohort 2

Individuals without history of PDAC meeting any of the following criteria:

1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+
2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family
3. 1 FDR with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member

Cohort 3

Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)

Cohort 4

Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.

Cohort 5

Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.

Cyst Cohort

Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)

Cohort 6a

Individuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria:

1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11

Cohort 6b

Individuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria:

1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
3. Diagnosed ≤ age 45

Cohort 6c

Individuals with newly diagnosed early stage (stage I or stage II) PDAC seen at a PRECEDE site that do not meet the criteria for 6a or 6b.

Cohort 6d

Individuals with PDAC seen at a PRECEDE site that do not meet the criteria for 6a, 6b, or 6c.

Primary outcome measure

  • Development of PDAC [ Time Frame: Through study completion, an average of 6 years ]

Central Contacts and Locations

Locations

Honor Health Research Institute

Recruiting

Scottsdale, Arizona, United States, 85258

Contacts

Principal Investigator:

Erkut Borazanci, MD

Providence Health and Services

Recruiting

Burbank, California, United States, 91505

Contacts

Principal Investigator:

Ora Gordon, MD, MS. FACMG

City of Hope

Recruiting

Duarte, California, United States, 91010

Contacts

Diamond Ward

diward@coh.org

Principal Investigator:

James Lin

UC San Diego Moores Cancer Center

Recruiting

La Jolla, California, United States, 92093

Contacts

Principal Investigator:

Diane Simeone, MD

Cedars-Sinai Medical Center

Recruiting

Los Angeles, California, United States, 90048

Contacts

Principal Investigator:

Srinivas Gaddam

UCLA Health

Recruiting

Los Angeles, California, United States, 90095

Contacts

Principal Investigator:

Timothy Donahue, MD

Hoag

Recruiting

Newport Beach, California, United States, 92663

Contacts

Principal Investigator:

Michael Demeure, MD

UC Irvine Health

Recruiting

Orange, California, United States, 92868

Contacts

Blake Johnson

blakej@hs.uci.edu

Principal Investigator:

Jennifer Valerin, MD, PhD

UC Davis

Recruiting

Sacramento, California, United States, 95817

Contacts

Principal Investigator:

Edward Kim, MD, PhD

University of California, San Francisco (UCSF)

Recruiting

San Francisco, California, United States, 94143

Contacts

Principal Investigator:

Margaret Tempero, MD

Yale University

Recruiting

New Haven, Connecticut, United States, 06510

Contacts

Principal Investigator:

James Farrell

Mayo Clinic Jacksonville

Recruiting

Jacksonville, Florida, United States, 32224

Contacts

Principal Investigator:

Yan Bi

University of Miami

Recruiting

Miami, Florida, United States, 33136

Contacts

Casper Ruiz Ruiz

cxr1353@med.miami.edu

Principal Investigator:

Dan Sussman

Moffitt Cancer Center

Recruiting

Tampa, Florida, United States, 33612

Contacts

Principal Investigator:

Jenny Permuth

Emory University Hospital

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Principal Investigator:

Saurabh Chawla, MD, AGAF, FACG, FASGE

Illinois CancerCare

Recruiting

Bloomington, Illinois, United States, 61704

Contacts

Principal Investigator:

Kimberly Ku, MD

University of Chicago Medicine

Recruiting

Chicago, Illinois, United States, 60637

Contacts

Principal Investigator:

Sonia Kupfer, MD

NorthShore University HealthSystem

Recruiting

Evanston, Illinois, United States, 60201

Contacts

Principal Investigator:

Melissa Hogg, MD

University of Kansas Medical Center

Recruiting

Kansas City, Kansas, United States, 66160

Contacts

Jodi Claybaugh

jclaybaugh@kumc.edu

Principal Investigator:

Ajay Bansal, MD

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, United States, 02114

Contacts

Principal Investigator:

Daniel Chung

Umass Memorial Medical Center

Recruiting

Worcester, Massachusetts, United States, 01655

Contacts

Principal Investigator:

James Lindberg, MD

University of Michigan

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Principal Investigator:

Elena Stoffel

Beaumont/Corewell Health

Recruiting

Royal Oak, Michigan, United States, 48073

Contacts

Principal Investigator:

Dana Zakalik, MD

University of Nebraska Medical Center

Recruiting

Omaha, Nebraska, United States, 68198

Contacts

Principal Investigator:

Kelsey Klute

Hackensack Meridian Health

Recruiting

Hackensack, New Jersey, United States, 07601

Contacts

Christianna Torres

christianna.torres@hmhn.org

Principal Investigator:

Rosario Ligresti, MD

Icahn School of Medicine At Mount Sinai

Recruiting

New York, New York, United States, 10029

Contacts

Principal Investigator:

Aimee Lucas

Columbia University Irving Medical Center

Recruiting

New York, New York, United States, 10032

Contacts

Katharine Godfrey

kb3217@cumc.columbia.edu

Principal Investigator:

Fay Kastrinos

University of Rochester Medical Center

Recruiting

Rochester, New York, United States, 14642

Contacts

Principal Investigator:

Darren Carpizo

White Plains Hospital

Recruiting

White Plains, New York, United States, 10601

Contacts

Principal Investigator:

Joshua Raff, MD

The Ohio State University

Recruiting

Columbus, Ohio, United States, 43210

Contacts

Principal Investigator:

Philip Hart, MD

Oregon Health & Science University

Recruiting

Portland, Oregon, United States, 97239

Contacts

Dove Keith

keithd@ohsu.edu

Principal Investigator:

Aaron Grossberg

University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Principal Investigator:

Bryson Katona

Fox Chase Cancer Center

Recruiting

Philadelphia, Pennsylvania, United States, 19111

Contacts

Eberechukwu Muoneke

eberechukwu.muoneke@fccc.edu

Principal Investigator:

David Weinberg, MD, MSc

University of Pittsburgh Medical Center (Upmc)

Recruiting

Pittsburgh, Pennsylvania, United States, 15232

Contacts

Principal Investigator:

Randy Brand

University of Tennessee Graduate School of Medicine

Recruiting

Knoxville, Tennessee, United States, 37930

Contacts

Tiffany Johnson

thjohnson@utmck.edu

Principal Investigator:

James McLoughlin, MD

Huntsman Cancer Institute

Recruiting

Salt Lake City, Utah, United States, 84112

Contacts

Principal Investigator:

Whitney Espinel, MMSc, GC

University of Virginia

Recruiting

Charlottesville, Virginia, United States, 22903

Contacts

Evelyn Garcia

ev4pd@uvahealth.org

Principal Investigator:

Todd Bauer, MD

Inova Schar Cancer Institute

Recruiting

Fairfax, Virginia, United States, 22031

Contacts

Principal Investigator:

Raymond Wadlow, MD

VCU Massey Comprehensive Cancer Center

Recruiting

Richmond, Virginia, United States, 23298

Contacts

Faith McFadden

mcfaddenfr@vcu.edu

Principal Investigator:

Jose Trevino, MD

University of Washington

Recruiting

Seattle, Washington, United States, 98195

Contacts

Lisa Ann Lai

lail@uw.edu

Principal Investigator:

Teri Brentnall

British Columbia Cancer Agency

Recruiting

Vancouver, British Columbia, Canada

Contacts

Principal Investigator:

Intan Schrader

University Health Network

Recruiting

Toronto, Ontario, Canada

Contacts

Principal Investigator:

Robert Grant

McGill University Health Centre

Recruiting

Montreal, Quebec, Canada

Contacts

Principal Investigator:

George Zogopoulos

More Information

Sponsor

Arbor Research Collaborative for Health

Last update posted

Jul 22, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Arbor Research Collaborative for Health on 2026-07-22.